Senior Investigator at The Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center.
Rising Mucormycosis Cases Drive Efforts for Spotlight on Treatment Research
Ashraf S. Ibrahim, PhD, outlines safety studies and the potential of this antibody therapy for treating this rare fungal infection, which is seemingly becoming less rare.
Read More
Humanizing Monoclonal Antibodies for Mucormycosis Treatment
Ashraf S. Ibrahim, PhD, details over 20 years of research on a spore-coating protein and the development of VX-01 to block fungal tissue invasion.
VX-01 Monoclonal Antibody Targets Mucormycosis by Blocking Angioinvasion
Ashraf S. Ibrahim, PhD, discusses how VX-01 prevents fungal invasion of blood vessels and enhances immune response in immunocompromised patients.